## **SUBJECT: Medical Nuclear Biological and Chemical Defense Materiel (MNBCDM)**

**1. PURPOSE:** Centrally fund and manage the Individual Service Member (IMS) initial issue requirements for medical nuclear, biological, and chemical defense materiel (MNBCDM) for Army forces. This materiel is called Deployable Force Packages (DFP)..

## 1. **FACTS:**

- a. All releases of centrally funded MNBCDM are validated and approved by The Office of The Surgeon General, Operations Division (DSN 761-8186/8052; COM 703-681-8186/8052). IMSA(s) will sent and email message to OTSG, OPSCENTER21 containing the following:
  - 1. Name of the Unit:
  - 2. Installation unit will deploy from:
  - 3. Number of PAX:
  - 4. Number of PAX on flight status:
  - 5. Date materiel is required for deploying personnel:
  - 6. Number of working dogs:
  - 7. Unit or TCS order number:
  - 8. Unit POC:
  - 9. Telephone Number:
  - 10. Email address:
- b. Materiel included in the DFP program:

Nomenclature	National Stock Number (NSN)	Basis of Issue (BOI)
Mark I Kits	6505-01-174-9919	3 per soldier
CANA	6505-01-274-0951	1 per soldier
PBT	6505-01-178-7903	21 tabs per soldier
Antibiotics:		30 tablets per soldier
Ciprofloxacin	6505-01-491-2834	•
Doxycycline	6505-01-491-5506	
Soldier's Guide MNBCDM	7610-01-492-7703	1 per soldier

Note: (1) PBT may only be issued from the storage activities to Army personnel with the written permission of The Surgeon General, even though the product was approved by the FDA in February 2003. No exceptions.

- (2) Each soldier will receive 30 tablets (15 days of supply (DOS)) of either the Ciprofloxacin or Doxycycline.
- (3) Potassium Iodide is being added to the OCONUS DFPs.
- c. Individual Service Member (ISM) initial issue materiel is assigned project code DH1. These assets are centrally funded and managed. Materiel is free issued to deploying troops.
- d. Mark I Kits are being replaced by the Nerve Agent Antidote (ATNAA), NSN 6505-01-362-7427 on a one for one basis.
- e. Skin Exposure Reduction Paste Against Chemical Warfare Agents (SERPACWA), NSN 6505-01-483-7162; is being added to the DFPs in FY03. Basis of issue will be 6 per soldier.
- f. In FY02, funding was provided to procure a limited number of MES, Chemical Agent Patient Treatment, LIN M23673 push packages. These push packages contain the potency and dated (P&D) items, and blowers/accessories for the chemical wrap. Packages were procured and distributed in FY02/03. Each year a limited amount of funding will be provided to buy additional push packages.

g. Excluded from the centrally managed program is the MNBCDM required as components of MESs (excluding the MES, Chemical Agent Patient Treatment), Rapid Response Teams, Chemical Accident/Incident Response Assistance (CAIRA). These requirements are united/command funded.
1. The AAC A MNBCDM requires special processing procedures. Required exception data is the unit's Unit Identification Code (UIC) and the reason for the order.
2. OTSG/MEDCOM approval is required for items that do not fall in the categories listed in

## 2. REFERENCES:

- a. SB 8-75-S7, Chapter 6. Medical Nuclear, Biological and Chemical Defense Materiel (MNBCDM)
- b. MEDCOM, Operations Management Bulletin, No 12-02.

## 3. **POINT OF CONTACTs**:

paragraph f above.

- a. Tammy Dundus, USAMMA, DSN 343-4421 for the replenishment of DFP assets and processing of AAC A requisitions.
- b. Teresa Bess, USAMMA, DSN 343-4406 for QC/QC questions to include disposition of excess or expired stocks.